Capricor Therapeutics (CAPR) Misses Q3 EPS by 2c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.29), $0.02 worse than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'
• Oppenheimer Starts Viatris (VTRS) at Outperform